ArticleScientific reports2026
The triglyceride HDL cholesterol ratio predicts sarcopenia risk in an aging National cohort from China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for identifying prevalent sarcopenia in Chinese patients with Cardiovascular-Kidney-Metabolic Syndrome.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the association between the triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio and the odds of sarcopenia in elderly individuals in China. The study population comprised 2,481 participants aged 60 years or older from the China Health and Retirement Longitudinal Study (CHARLS). All participants were free of sarcopenia at baseline in 2011 and completed follow-up assessments in 2015. Multivariable logistic regression models were applied to examine the association between the TG/HDL-C ratio and incident sarcopenia. Subgroup, sensitivity, and post hoc power analyses were performed, and restricted cubic spline models were used to examine potential nonlinear associations. Compared with the lowest quartile (Q1), participants in Q3 and Q4 of TG/HDL-C ratio had significantly lower odds of incident sarcopenia (OR 0.34 [95% CI 0.20–0.55] for Q3; OR 0.55 [95% CI 0.36–0.84] for Q4). A consistent inverse association was observed when TG/HDL-C ratio was analyzed as a continuous variable (OR 0.83 [95% CI 0.74–0.93]). Subgroup analyses showed that the protective association was more pronounced in males. In Chinese older adults, a higher TG/HDL-C ratio is associated with reduced risk of developing sarcopenia, particularly among men.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.